I'm surprised you missed the dosing announcement on 18 Jan 2022.

What?  No, I didn't miss that.  It was the announcement that dosing had started at the first site, the University of Alberta Hospital in Edmonton.

I'm surprised you missed the Feb 17 dosing announcement!  That one said that a Brazilian site had started dosing AND one in Calgary AND a further six sites would be starting soon.  

So.  Am I to believe that almost 3 months later (May 9, Phase II stopped), only "one or a few people in Edmonton and maybe the same number in Brazil" had been dosed as you said?  Seems unlikely to me.  Way more dosed would be my estimate. By May 9 they were well into dosing at three sites, possibly up to a total of nine.

if you can show us any financials or any MD&A that shows they had $3 or $4 million to complete that trial I'll gladly redact my assumptive statement

You also stated they "didn't have the financing in place to complete that trial".  

IMO, you're just guessing on both statements . May 5, 2021, RVX did a $6 million financing in part to fund "clinical trial activities".  At the time the trial was stopped they were dosing at least three sites and as many as nine.  The trial was only 100 patients.  No way it was going to cost an additional $3 to $4 million.  

If that Phase II trial had shown efficacy, the stock would have zoomed up several bucks.  And they had to know if they stopped it without explanation, the stock would crater.  IMO they would have done another small financing if they were short a few bucks on trial expenses.

I can no longer find it at clincaltrials.gov, but as I recall, the Phase III was to include 3,200 patients.  If the current one is in that ballpark, they can fund that but couldn't fund a Phase II with 100 patients?

And if cancelling the Phase II was just a financing issue, why not say so?  Why leave it hanging for investors to guess something worse?

FWIW, I agree with this.